Journal
THORAX
Volume 70, Issue 5, Pages 451-457Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2014-206449
Keywords
-
Categories
Funding
- National Institute for Health Research (NIHR)'s Programme Grants for Applied Research Programme [RP-PG-0407-10398]
- Asthma UK [AUK-AC-2012-01, 11/040] Funding Source: researchfish
- Medical Research Council [G1000758B, MC_U190081977, MC_U190092710, G1000758] Funding Source: researchfish
- National Institute for Health Research [RP-PG-0407-10398, RP-PG-0609-10181] Funding Source: researchfish
- MRC [MC_U190081977, MC_U190092710] Funding Source: UKRI
Ask authors/readers for more resources
Rationale Asthma exacerbations are commonly precipitated by viral upper respiratory infections (URIs). Vitamin D insufficiency associates with susceptibility to URI in patients with asthma. Trials of vitamin D in adults with asthma with incidence of exacerbation and URI as primary outcome are lacking. Objective To conduct a randomised controlled trial of vitamin D-3 supplementation for the prevention of asthma exacerbation and URI (coprimary outcomes). Measurements and methods 250 adults with asthma in London, UK were allocated to receive six 2-monthly oral doses of 3 mg vitamin D-3 (n=125) or placebo (n=125) over 1 year. Secondary outcomes included asthma control test and St George's Respiratory Questionnaire scores, fractional exhaled nitric oxide and concentrations of inflammatory markers in induced sputum. Subgroup analyses were performed to determine whether effects of supplementation were modified by baseline vitamin D status or genotype for 34 single nucleotide polymorphisms in 11 vitamin D pathway genes. Main results 206/250 participants (82%) were vitamin D insufficient at baseline. Vitamin D-3 did not influence time to first severe exacerbation (adjusted HR 1.02, 95% CI 0.69 to 1.53, p=0.91) or first URI (adjusted HR 0.87, 95% CI 0.64 to 1.16, p=0.34). No clinically important effect of vitamin D-3 was seen on any of the secondary outcomes listed above. The influence of vitamin D-3 on coprimary outcomes was not modified by baseline vitamin D status or genotype. Conclusions Bolus-dose vitamin D-3 supplementation did not influence time to exacerbation or URI in a population of adults with asthma with a high prevalence of baseline vitamin D insufficiency.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available